2015
DOI: 10.4172/2329-6925.1000220
|View full text |Cite
|
Sign up to set email alerts
|

Why is an IABP not the Answer to Cardiogenic Shock after Percutaneous Coronary Intervention? Is it that Noradrenaline helps, Especially by Improving the RV Function in Addition to LV Function? A View Point

Abstract: We review the role of noradrenaline in cardiogenic shock. We describe our experience with the same after percutaneous coronary intervention, mostly primary angioplasty. The side effects of noradrenaline, the results of the SOAP 2 and the IABP Shock trial are also discussed. Noradrenaline is surprisingly a useful drug. So we want to share our experience with it.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 12 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?